|drug923||Coronary artery calcium score and cardiac computed tomographic angiography Wiki||0.71|
|drug1878||Low Dose (10 mg) Control Wiki||0.71|
|drug297||Arm exercise electrocardiographic stress test Wiki||0.71|
|drug3527||Treadmill electrocardiographic stress test Wiki||0.71|
|drug2703||Pulmonary Vascular Permeability Index Wiki||0.71|
|drug2841||Regadenoson myocardial perfusion imaging stress test Wiki||0.71|
|drug1267||Extravascular Lung Water Index Wiki||0.71|
|drug1552||Hydroxychloroquine and Azithromycin Wiki||0.50|
|D011654||Pulmonary Edema NIH||0.82|
|D000075902||Clinical Deterioration NIH||0.50|
|D011665||Pulmonary Valve Insufficiency NIH||0.27|
There are 2 clinical trials
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of PB1046 by improving the clinical outcomes and increasing days alive and free of respiratory failure in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.
Description: PaO2:FiO2 ratio is the ratio of partial pressure of arterial oxygen to percentage of inspired oxygenMeasure: Development of ARDS (PaO2:FiO2 ratio < 300 mm Hg) during hospitalization Time: Any time point between injection initiation and Day 28
Description: Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapyMeasure: Reduction in hospital resource utilization defined as a composite of:total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy Time: 28 days
Covid-19 also primarily affects endothelium that line up the alveoli. The resulting hypoxemia may differ from "typical" Acute Respiratory Distress Syndrome (ARDS) due to maldistribution of perfusion related to the ventilation. Thus, pathophysiology of Covid-19 ARDS is different, which requires different interventions than typical ARDS. The investigators will assess whether extravascular lung water index and permeability of the alveolar capillary differs from typical ARDS with transpulmonary thermodilution (TPTD) technique. Extravascular Lung Water Index (EVLWI) and Pulmonary Vascular Permeability Index (PVPI) will be compared.
Description: The amount of fluid accumulated in the lung measured by transpulmonary thermodilution (ml/kg)Measure: Extravascular Lung Water Index Time: 1 day
Description: Integrity of the alveolocapillary barrier measured by transpulmonary thermodilutionMeasure: Pulmonary vascular permeability index Time: 1 day
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports